High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Tempus AI Inc. (NASDAQ:TEM) is one of the 10 worst artificial intelligence stocks under $30 according to short sellers. During the first week of June, Tempus AI Inc. (NASDAQ:TEM) shared the impending clinical availability for its advanced sequencing test, xH. It detects oncologic targets within bone marrow and peripheral blood samples, based on whole-genome sequencing […]
Tempus AI, Inc. (NASDAQ:TEM) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On June 11, 2026, Tempus AI, Inc. (NASDAQ:TEM) announced that a multi-center validation of its artificial intelligence ECG software for predicting one-year atrial fibrillation or flutter risk was published in Heart Rhythm. The company stated the […]
We just covered the 10 Stocks That Will 10X According to Social Media. Tempus AI (NASDAQ:TEM) ranks #7 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 33 Tempus AI (NASDAQ:TEM) runs cancer diagnostic tests and sells the resulting data and AI tools to pharmaceutical companies and research institutions. […]
Tempus AI, Inc. (NASDAQ:TEM) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 3, Tempus AI, Inc. (NASDAQ:TEM) reported that it launched an open-source digital pathology consortium, alongside Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center, aiming to build a scalable platform and viewer. Chief of Pathology […]
Wondering if Tempus AI at around US$47.82 is starting to look interesting, or if the stock still carries more risk than reward for you. The stock has risen 3.0% over the past week and 4.2% over the past month, although it is still down 23.3% year to date and has fallen 32.9% over the past year. Recent coverage has focused on Tempus AI as part of the broader conversation around AI in healthcare and life sciences, with investors weighing its long term potential against ongoing execution risks...
Tempus AI Inc (NASDAQ:TEM) is one of the 12 Best Mid-Cap AI Stocks to Buy According to Analysts. On May 29, Tempus AI Inc (NASDAQ:TEM) announced that it had received FDA approval for a tumor-only indication for its xT CDx sequencing platform. This makes the company the only laboratory to have both tumor-only and tumor-normal […]
Market snapshot and recent moves Tempus AI (TEM) has drawn fresh attention after a strong single-day move, with the stock up about 10% on the latest close at US$52.26, compared with weaker returns over the past month. See our latest analysis for Tempus AI. That move comes after mixed momentum over the year, with the 7 day share price return of 1.89% set against a year to date share price decline of 16.2% and a 1 year total shareholder return that is down 10.91%. Recent strength is emerging...
Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Crushing the Market With Surging Returns. Tempus AI saw its share prices jump by 10 percent on Thursday to finish at $52.56 apiece, as investors cheered its formation of a consortium alongside two health institutions to support the development of an open-source digital pathology platform […]
Tempus (TEM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]
In recent days, Tempus AI announced a string of oncology-focused product advances, including FDA approval of its xT CDx tumor-only sequencing assay, major upgrades to its AI-enabled Next and Hub platforms, and new tools like Preview, Lens, and the ArteraAI Prostate Test (mHSPC) that deepen its role in precision cancer care. Taken together, these moves highlight Tempus AI’s effort to turn its multimodal data and foundation models into end-to-end clinical and biopharma solutions, from faster...
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the data from our partner Ortex.com, which utilizes the latest information from stock lenders to estimate short interest changes for thousands of publicly traded companies, this report will screen for some of biggest changes in short interest as a percentage of free float and days-to-cover ratios while also consi
Tempus AI’s latest analyst update keeps the fair value target unchanged at US$67.20 per share, even as model assumptions are fine tuned. The steady target sits against a mixed backdrop, where some analysts highlight long term potential tied to partnerships while others have recently cut price targets and flagged execution risk. As you read on, you will see how these differing views and incremental model tweaks shape the evolving Tempus AI story and what it could mean for your own research...
Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is delivered through Tempus AI's platform and is designed to support more personalized treatment decisions for a large group of prostate cancer patients. Tempus AI reported a record research presence at the ASCO 2026 Annual Meeting, with 37 abstracts accepted. Tempus AI, trading at $46.66, is drawing...
Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold play in the AI sector. In a span of a week, Tempus AI, Inc. (NASDAQ:TEM) made two announcements that add to its growing pipeline of clinical and pharma partnerships. The freshest update came […]
Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best ARK Stocks to Buy Right Now. On May 14, Tempus AI, Inc. (NASDAQ:TEM) announced a collaboration with Bristol Myers Squibb to maximize clinical trials. The partnership will use multimodal data and AI to improve trial design and boost the probability of technical and regulatory success […]
Recent share performance and business profile Tempus AI (TEM) has drawn investor attention after a period in which the stock fell 22% over the past month and 17% over the past 3 months, while its core healthcare technology operations remain focused on clinical and research applications. See our latest analysis for Tempus AI. At a share price of $43.62, Tempus AI has seen its recent momentum fade, with the share price return down 10% over the past week, 22% over the past month and 30% year to...
Tempus AI and Bristol Myers Squibb are expanding their collaboration to apply AI analytics and real world data to oncology and neuroscience drug development. The partnership focuses on using Tempus AI's multimodal patient data to inform clinical trial design, including programs in oncology and Alzheimer's disease. The agreement highlights growing pharmaceutical interest in AI driven tools that can address complex challenges in precision medicine research. Tempus AI, listed as NasdaqGS:TEM,...
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful ... 7 Healthcare AI Stocks Under $50 With Huge Upside Potential
By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with CTA313 in systemic lupus erythematosus is highly encouraging, with 100% of patients achieving an SRI-4 […]
We just covered Cathie Wood’s 11 Biggest AI and Data Center Stock Picks. Tempus AI Inc. (NASDAQ:TEM) ranks #5 (see Cathie Wood’s 5 Biggest AI and Data Center Stock Picks). Cathie Wood’s Stake: $446,275,249 Tempus AI Inc. (NASDAQ:TEM) is an AI healthcare play in Cathie Wood’s portfolio. It’s a healthcare diagnostics and data platform that builds large-scale […]
Tempus AI (NasdaqGS:TEM) and Lucent Diagnostics, a Quanterix company, are teaming up to bring an AI-enabled care pathway and blood test for Alzheimer's detection into clinical workflows. The collaboration centers on integrating the LucentAD Complete blood-based biomarker panel into Tempus's Next platform for use by neurologists. The partnership extends Tempus AI's reach beyond oncology into neurology and broader precision medicine applications. Tempus AI, trading at around $49.43 per share,...
Beneath the headline noise of a Q1 2026 beat and raised guidance, the critical insight for Tempus AI lies in a structural tug of war between an accelerating data moat and a currently elevated cost structure. The market is focusing on the 36% year over year top line growth to $348.1 million. The true alpha driver is hidden within the unit economics of the Data and Applications segment. This division is actively shifting the company from a traditional diagnostics provider to a recurring revenue he
Tempus AI (NASDAQ:TEM) reported first-quarter 2026 revenue of $348.1 million, up a little over 36% year over year, as the company posted growth across both its diagnostics and data and applications segments and raised its full-year outlook. Founder and CEO Eric Lefkofsky said diagnostics revenue ca
Moby summary of Tempus AI, Inc.'s Q1 2026 earnings call
Tempus (TEM) delivered earnings and revenue surprises of +38.10% and +0.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Investors are watching Tempus AI (NASDAQ:TEM) ahead of first-quarter results due after the close tomorrow. The stock burst into investor consciousness in January 2025 after Nancy Pelosi disclosed a position, ran past $100, and has since shed nearly half its value. From Pelosi Halo to Show-Me Story Pelosi’s market-beating track record has turned her trades ... Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?
In April 2026, the Keck School of Medicine of USC and Keck Medicine of USC announced a broad collaboration with Tempus AI to embed its genomic testing, AI tools, and data platform across more than 1.5 million annual patient visits in their Southern California network. This partnership not only expands Tempus AI’s clinical footprint but also deepens its access to real-world oncology data, reinforcing the company’s core data-network advantage in precision medicine. With this USC collaboration...
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.